Table 3.
Pharmacological effects | Mechanisms | References |
---|---|---|
(I) Experimental studies | ||
| ||
↑ CAT, SOD, and GST; | ||
Antioxidant activity | ↓ LDH | [23] |
↑ CAT, SOD, and GSH | [24] | |
↓ TBARS | [26] | |
| ||
Anti-inflammatory effects | ↓ LPS-induced NO production | [28–30] |
| ||
Anticancer effects | ↑ Cell differentiation | [35] |
↓ Proliferation of cancer cells | [3, 36] | |
↑ IL-2 and IFN-c | [38] | |
↓ Tumour growth | ||
↓ Cell proliferation, migration, and cell cycle arrest at G2/M phase | [42] | |
↓ E-selectin expression | [40] | |
↓ Janus tyrosine kinases-signal transducers and activators of transcription, phosphatidylinositol 3-kinase and NF-κB signalling pathways, suppression of hsp 90, cyclins, and cyclin-dependent kinases, MMPs and growth factors | ||
↑ Tumor suppressor proteins p53 and p21 | [41] | |
| ||
Immunomodulatory effect | ↑ Antibody production | [43] |
↓ Delayed-type hypersensitivity response | ||
↑ Proliferation of human peripheral blood lymphocytes | ||
Key cytokines and the expression | [1, 2, 44] | |
| ||
↓ ALT activity | [50] | |
Hepatoprotective effects | ↓ Concanavalin A-induced liver injury and hepatocyte apoptosis | [52] |
↓ GOT, GPT, ACP, and ALP levels Losses of HBsAg, HBeAg, and HBV DNA |
[54, 56] | |
| ||
Antimicrobial effects | Acted against herpes simplex virus 1 (HSV-1) | [59] |
Acted against nine bacterial strains such as | ||
Salmonella typhimurium, Escherichia coli, | ||
Shigella sonnei, Staphylococcus aureus, | [63] | |
Pseudomonas aeruginosa, Streptococcus pneumonia, | ||
Streptococcus pyogenes, Legionella pneumophila, and Bordetella pertussis | ||
| ||
↓ Herpes simplex virus (HSV) | [62, 68] | |
Antiviral effects | Human immunodeficiency virus (HIV) | [3, 67] |
Flaviviruses and pestiviruses | [69] | |
Dengue virus (DENV1) | [71] | |
| ||
Larvicidal and ovicidal effects | Affected the larval growth of Anopheles stephensi | [81] |
Ovicidal activity against various age groups of Aedes Stephens | [82] | |
Larvicidal and ovicidal activities against Culex quinquefasciatus Say and Aedes aegypti L. | [83] | |
| ||
Renoprotective effects | ↓ Gentamicin-induced increase in serum creatinine, | [86] |
serum urea, and blood urea nitrogen levels | ||
| ||
↓ Spermatogenesis | [94] | |
Antifertility effects | ↓ Degenerative changes in the seminiferous tubules, regression of Leydig cells, and regressive and/or degenerative changes in the epididymis, seminal vesicle, | [94] |
↓ ventral prostate, and coagulating glands | [94] | |
| ||
Antihyperglycemic activity | ↓ TG | [24] |
↓ Blood glucose level | [99, 100, 102] | |
| ||
Hypolipidemic effects | ↓ TC, TG, HDL-TC, and LDL-TC | [109] |
↓ Blood glucose, triglyceride, and LDL | [110] | |
| ||
Cardiovascular effects | Limiting blood flow to the brain, heart, and bodies of other organs | [112] |
Protect rat cardiomyocytes against | ||
hypoxia injury by increasing GSH | [113] | |
and antioxidant enzyme | ||
↓ Coronary perfusion pressure | [114] | |
| ||
↓ Platelet-activating factor (PAF) | [15] | |
Inhibitory effects on platelet aggregation | ↑ eNOS-NO/cyclic GMP pathway | [120] |
↓ PLCγ2-PKC and PI3 kinase/Akt-MAPKs | ||
| ||
Inhibitory effects on NF-kappa B activation | ↓ NF-κB via the covalent modification of reduced Cys62 of p50 | [13] |
↓ NF-κB via blocking the binding of NF-κB oligonucleotides to nuclear proteins | [128] | |
| ||
(II) Clinical studies | ||
| ||
Anti-HIV effect | ↑ CD4+ lymphocyte count | [3] |
↓ gp120-mediated cell fusion of HL2/3 cells with TZM-bl cells | [135] | |
| ||
Effects on upper respiratory tract infections | ↓ Relieving the symptoms of fever and sore throat | [73] |
Tiredness, sleeplessness, sore throat, and nasal secretion | [136] |
CAT: catalase; SOD: superoxide dismutase; GST: glutathione-S-transferase; LDH: lactate dehydrogenase; TBARS: thiobarbituric-acid-reactive substances; LPS: lipopolysaccharides; NO: nitric oxide; IL-2: interleukin-2; IFN-c: interferon-c; GOT: glutamate oxaloacetate transaminase; GPT: glutamate pyruvate transaminase; ALP: alkaline phosphatase; ACP: acid phosphatase; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B “e” antigen; ALT: alanine aminotransferase; TC: total cholesterol; TG: triglyceride; LDL: low-density lipoprotein; HDL: high-density lipoprotein; GHS: reduced glutathione; PLC-γ2: phospholipase C; PKC: protein kinase C; MAPK: mitogen-activated protein kinase; cGMP: cyclic guanosine monophosphate; eNOS: endothelial nitric oxide synthase; HSP: heat shock protein; MMP: matrix metalloproteinases.